Login to Your Account



Fampridine-SR Data Sends Acorda Stock Through Roof

By Aaron Lorenzo


Tuesday, September 26, 2006
Shares in Acorda Therapeutics Inc. rocketed by more than 282 percent Monday on positive findings from a Phase III study of Fampridine-SR in multiple sclerosis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription